Connect with top gaming leaders in Los Angeles at GamesBeat Summit 2023 this May 22-23. Register here.
The Silicon Valley company’s flagship product is a small, round device that lets people track their vitals at home. But the company says it’s actually building a whole family of mobile medical products for consumers.
“Scanadu is right at the heart of the next generation of computing which combines mobility, sensors, cloud, and big data,” said investor Jerry Yang, the former chief executive and cofounder of Yahoo, in a statement. “I am bullish on Scanadu and its potential to revolutionize the way we think about our health.”
The funding round was led by Fosun International and Tencent Holdings Limited, with participation from China Broadband Capital and Iglobe Partners of Singapore. Earlier investors Relay Ventures, Redmile Group, Ame Cloud Ventures, and Three Leaf Ventures (an affiliate of The Broe Group) also participated.
With this round, Scanadu has raised $49.7 million in total funding to date.
“We continue to build out our family of products and move down the path to regulatory clearance in the U.S. and China,” said Scanadu founder and CEO Walter De Brouwer.
Scanadu says it will complete shipment of its first set of investigational Scanadu Scout devices to its more than 8,000 Indiegogo supporters. The device measures heart rate, core body temperature, blood oxygenation, and cuffless and calibration-free systolic and diastolic blood pressure in one scan, and shares those results to an app on Android and iOS smartphones.
Scanadu is currently working toward FDA submission and approval for that device, as well as Scanadu Urine (formerly known as ScanaFlo), an at-home urine test that similarly shares important health data to your smartphone.
Scanadu has been in operation since 2012.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.